Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.64 |
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | FECH | P22830 | 1/20 | 0.60 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.60 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27093466 | 1.00 | ERBB2 (0.64) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167675 | 0.90 | ERBB2 (0.64) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL21563124 | 0.89 | ERBB2 (0.63) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29888215 | 0.89 | ERBB2 (0.60) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29936028 | 0.89 | ERBB2 (0.60) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167353 | 0.89 | ERBB2 (0.60) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167673 | 0.86 | ERBB2 (0.60) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL21563122 | 0.86 | ERBB2 (0.66) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26697702 | 0.84 | ERBB2 (0.62) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26006688 | 0.84 | ERBB2 (0.63) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459485-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221227-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2022-10-20 | — | — | WO | disclosed |